Coherus Rolls Out YUSIMRY At $995 Per Carton In US

RTTNews | 850 дней спустя
Coherus Rolls Out YUSIMRY At $995 Per Carton In US

(RTTNews) - Coherus BioSciences, Inc. (CHRS) announced Monday that YUSIMRY (adalimumab-aqvh) is now available for commercial sale in the United States at a list price of $995 per carton for two 40 mg/0.8 mL autoinjectors.

The pricing represents a discount of more than 85% to Humira (adalimumab), currently priced at $6,922 per carton of two pens.

YUSIMRY is presented in a state-of-the-art autoinjector and includes Coherus' proprietary non-stinging, citrate-free formulation and a 29-gauge needle.

YUSIMRY, approved in 2021 by the U.S. Food and Drug Administration, is a tumor necrosis factor blocker indicated to reduce the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, and to treat Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

YUSIMRY Solutions - Coherus' patient services platform - will ensure improved access and a fast and seamless experience as patients start or switch to YUSIMRY treatment based on a determination by their healthcare provider.

Тэгов: CHRS
read more
Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus, Junshi Biosciences Say FDA Accepts Resubmission Of Toripalimab BLA

Coherus BioSciences, Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.
RTTNews | 1212 дней спустя
Swiss Market Settles Slightly Down

Swiss Market Settles Slightly Down

The Switzerland market ended slightly down on Thursday, after languishing in the red almost right through the day's session, with investors reacting to corporate earnings updates, and a report showing signs of an improved outlook in the Swiss economy.
RTTNews | 4ч 4мин назад
ECB Holds Interest Rates Steady Amid Uncertain Outlook

ECB Holds Interest Rates Steady Amid Uncertain Outlook

The European Central Bank maintained its key interest rates unchanged for a third policy session in a row on Thursday, as expected, as policymakers assessed that the outlook was broadly unchanged, but still uncertain due to global trade conflicts and geopolitical tensions.
RTTNews | 8ч 6мин назад
Eurozone GDP Growth Beats Expectations

Eurozone GDP Growth Beats Expectations

The euro area economy expanded at a faster pace in the third quarter as France and Spain reported strong growth, while Germany and Italy experienced stagnation, amid a highly uncertain outlook due to the ongoing trade policies and political instability. Gross domestic product climbed 0.2 percent sequentially in the September quarter, preliminary flash estimate from Eurostat showed on Thursday.
RTTNews | 8ч 51мин назад
Bay Street Likely To Open Weak

Bay Street Likely To Open Weak

Weak commodity prices, lower European stocks and U.S. and Canadian futures point to a negative start for the Canadian market on Thursday. The Federal Reserve and Bank of Canada lowered interest rates on Wednesday but have ruled out the possibility of another cut this year.
RTTNews | 9ч 43мин назад
German Economy Stagnates On Weaker Exports; Unemployment Falls

German Economy Stagnates On Weaker Exports; Unemployment Falls

The German economy stagnated in the third quarter, narrowly dodging a recession as higher U.S. tariffs damped exports and the optimism about the fiscal stimulus faded, while unemployment logged an unexpected moderate fall. Gross domestic product remained unchanged, as expected, following a revised decline of 0.2 percent in the second quarter, the preliminary estimate from Destatis revealed on T
RTTNews | 9ч 47мин назад